Results 211 to 220 of about 82,138 (252)
Some of the next articles are maybe not open access.
Développement professionnel continu (DPC)
2014C’est un devoir pour tout medecin, quels que soient sa specialite et son mode d’exercice, de veiller a developper ses connaissances et a ameliorer constamment ses pratiques professionnelles, comme le rappelle tres clairement l’article 11 du Code de deontologie medicale: «Tout medecin doit entretenir et perfectionner ses connaissances; il doit prendre ...
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2002
DPC-423 is a biphenylamine-containing amide which is under development by Bristol-Myers Squibb (formerly DuPont Pharmaceuticals) as a Factor Xa inhibitor for the potential treatment of thrombotic disorders [372092]. As of August 2000, DPC-423 was in phase I trials [380880].
openaire +3 more sources
DPC-423 is a biphenylamine-containing amide which is under development by Bristol-Myers Squibb (formerly DuPont Pharmaceuticals) as a Factor Xa inhibitor for the potential treatment of thrombotic disorders [372092]. As of August 2000, DPC-423 was in phase I trials [380880].
openaire +3 more sources
Gan to kagaku ryoho. Cancer & chemotherapy, 2004
After the introduction of DPC in 2003, cancer chemotherapy treatment was moved to our outpatient clinic. We have initiated an outpatient cancer chemotherapy center, and the chemotherapy regimens were developed for various kinds of cancer: 1 for esophageal, 7 for gastric, 9 for colon, 38 breast and 10 for hepato-biliary-pancreatic cancer.
openaire +1 more source
After the introduction of DPC in 2003, cancer chemotherapy treatment was moved to our outpatient clinic. We have initiated an outpatient cancer chemotherapy center, and the chemotherapy regimens were developed for various kinds of cancer: 1 for esophageal, 7 for gastric, 9 for colon, 38 breast and 10 for hepato-biliary-pancreatic cancer.
openaire +1 more source
DPC-083. DuPont Pharmaceuticals.
Current opinion in investigational drugs (London, England : 2000), 2002DPC-083 and DPC-961 are non-nucleoside reverse transcriptase inhibitors (NNRTIs) under development by DuPont Pharmaceuticals for the potential treatment of HIV infection [312865]. Phase I trials were completed by September 2000 [383661], and by April 2001, DPC-083 was in phase II trials as a once-daily oral dose in combination therapy, with phase III ...
openaire +1 more source